Biomarin Pharmaceutical (BMRN) Capital Expenditures Growth (1y) (2010 - 2026)
Biomarin Pharmaceutical (BMRN) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.65 Bn | 9.42 Bn | 571.21 Mn | 24.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.78% |
| Dec 31, 2025 | 108.51% |
| Sep 30, 2025 | 164.37% |
| Jun 30, 2025 | -115.30% |
| Mar 31, 2025 | -35.76% |
| Dec 31, 2024 | 153.32% |
| Sep 30, 2024 | -70.30% |
| Jun 30, 2024 | 213.20% |
| Mar 31, 2024 | 6.74% |
| Dec 31, 2023 | -127.52% |
| Sep 30, 2023 | 2,178.17% |
| Jun 30, 2023 | 50.38% |
| Mar 31, 2023 | -15.13% |
| Dec 31, 2022 | 2,051.62% |
| Sep 30, 2022 | -510.85% |
| Jun 30, 2022 | -47.00% |
| Mar 31, 2022 | 12.98% |
| Dec 31, 2021 | -73.64% |
| Sep 30, 2021 | 1,400.00% |
| Jun 30, 2021 | -600.74% |